47 results about "Plasma serum" patented technology

A method is provided for assessing allelic losses on specific chromosomal regions in melanoma patents. The method relies on the evidence that free DNA may be released in the plasma/serum of cancer patients allowing the detection of DNA with LOH in the plasma/serum of cancer patients by analysis for microsatellite markers. The amount of and specific allelic loss allows a prognosis to be made regarding tumor diagnosis and progression, tumor metastasis, tumor recurrence, and mortality.

The invention discloses a coronavirus rapid detection kit based on S protein ligand and ACE2 receptor competitive chromatography. The coronavirus rapid detection kit comprises quantum dot labeled ACE2protein, quantum dot labeled rabbit IgG, recombinant coronavirus spinous process protein S1, goat anti-rabbit IgG polyclonal antibody, an immunochromatographic test strip and other materials. The detection sensitivity is improved through quantum dot fluorescence labeling and multistage coupling amplification signals, the detection specificity is improved and the antibody research and developmentcycle is avoided by utilizing the ligand and receptor binding principle, the kit capable of rapidly detecting coronavirus is provided, and the biosafety in the detection process is guaranteed by establishing a virus inactivation system. The kit disclosed by the invention is suitable for detecting various biological samples and environmental samples such as oral mucosa liquid, respiratory tracts, whole blood, plasma, serum, excrement and the like, and can be applied to rapid detection of coronaviruses taking ACE2 as a receptor, such as SARS-CoV-19, SARS-CoV, HCoV-NL63 and the like.

The invention discloses a cirrhosis microRNA molecular marker composition, with sequence No. ranging from 1 to 13, as well as application of the molecular marker composition in preparing a cirrhosis personalized medicine diagnostic reagent. Due to a significant difference between content of a microRNA molecular marker of a cirrhosis patient in plasma/serum and content in plasma/serum in health control, cirrhosis patient can be effectively distinguished from people of the health control; in a process of applying medicines to the cirrhosis patient, administration can be stopped by guiding and assistance, when cirrhosis outcome microRNA molecular marker is adjusted to a normal level. Furthermore, the invention discloses a diagnostic kit for guiding personalized administration of the cirrhosis. The liver cirrhosis outcome microRNA molecular marker disclosed by the invention, when being used for guiding personalized administration of cirrhosis patients, has characteristics of being simple to operate, safe and noninvasive, high in specificity, high in sensitivity and easy in massive screening.

The invention provides a micro-fluidic chip. When total blood flow passes through a bifurcated branch channel port, blood cells are subjected to asymmetric shearing force on two sides, the blood cellsselect a main channel with the large flow speed and the small flow resistance to continue to advance, and part of blood plasma can enter a bifurcated branch channel. According to the micro-fluidic chip, the micro-fluidic chip constructed through a bifurcated multi-branch structure can achieve whole blood separation without exogenous power. When the micro-fluidic chip performs flow resistance adjustment through a flow resistance adjusting unit 130 located in the bifurcated branch channel, the collection efficiency of the blood plasma is adjusted. According to the micro-fluidic chip, capillarydriving force is provided through a capillary pump unit 140 located at a tail end, the functions of quantifying and collecting plasma/serum are achieved, and finally on-chip self-driven whole blood separation is achieved. The micro-fluidic chip provided by the invention shows huge application potential in the field of integrated and micro-miniaturized bedside instant detection.

The invention provides a hepatitis b /hepatic cirrhosis microRNA molecular marker combination, which comprises more than one micro RNA nucleic acid molecules selected from mir.146a-5p, miR-22-3P and miR-381.3P, and a purpose of the marker combination for preparing hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment kit. Due to a significant difference between content of a microRNA molecular marker of a hepatitis b/hepatic cirrhosis patient in plasma/serum and content in plasma/serum in health control, the hepatitis b/hepatic cirrhosis patient can be effectively distinguished from people of the health control; a chronic hepatitis b/hepatic cirrhosis disease state can be comprehensively analyzed, which can be used for guiding the patient treatment and usage of medication. The invention also provides a diagnostic kit for guiding the hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment. By using the hepatitis b/hepatic cirrhosis microRNA molecular marker and the diagnostic kit, infection diagnosis and/or prognosis assessment of the hepatitis b/hepatic cirrhosis patient can be guided, and the combination has the characteristics of simple operation, safety and no wound, high specificity, high sensitivity and easy massive screening.

The invention provides a preparation method of prp serum for repairing sport injury, and relates to the technical field of serum preparation. The preparation method of the prp serum for sports injury repair comprises the following steps: conveying anticoagulant blood formed by mixing whole blood and an anticoagulant, carrying out secondary nanofiltration and centrifugation on the anticoagulant blood to obtain plasma serums with different concentrations, mixing platelet-rich plasma serums prepared in advance with the plasma serums with different concentrations to obtain prp serums with different concentrations, and refrigerating to obtain the prp serum for sports injury repair. The prp serum can be mixed with sodium hyaluronate gel to be injected into the sport injury part, the environment of natural cartilage is fully simulated by means of the gel with high water content, and the prp serum is easy to degrade and non-toxic, so that the curative effect research of the prp serum for repairing the sport injury is facilitated, the optimal treatment concentration scheme is obtained, and the quick repair of the sport injury part is promoted.

The invention belongs to the fields of molecular biology and medical science, and provides a blood plasma miRNA spectrum used for predicting the chronic hepatitis b curative effect of an interferon. The miRNA spectrum comprises one or a plurality of miRNA in SEQ ID No.1-10. The invention also provides a corresponding high-efficiency and low-cost kit, a detection chip and a detection method. The method and the kit provided by the invention are used for detecting miRNA levels in blood plasma and blood serum. The method and the kit are suitable to be used clinically for determining the effectiveness of an interferon. Compared to other known related factors, the expression spectrum is an independent prediction factor. The combination of the expression spectrum and HBV drug-resistance mutation analysis assists in the practice of individualized treatment schemes, and finally in reducing treatment costs and improving complete response proportions.

The invention discloses application of FXYD3 as a gastric cancer diagnosis marker and a treatment target, and relates to the technical field of medical biological detection. According to the invention, a specific detection primer is constructed, which can be used for gastric cancer diagnostic reagent or kit, and can be used for detecting tissue specimens or blood samples such as blood plasma, blood serum and blood platelets. The invention also comprises application of the FXYD3 in preparation of a pharmaceutical composition for preventing or treating gastric cancer, and the drug can inhibit expression of the FXYD3. The FXYD3 has an important function in the occurrence and progress of gastric cancer, which can be used as a target for diagnosis and treatment, and has a good clinical application value.

The invention discloses a method for detecting a high-density lipoprotein subcomponent in a preeclampsia judgment process, which comprises the following steps: presetting a high-density lipoprotein HDL subcomponent analysis kit, obtaining a blood sample, and detecting the to-be-detected blood sample by using the high-density lipoprotein HDL subcomponent analysis kit; carrying out standing centrifugal treatment on the blood sample, separating out plasma/serum, and adding the plasma/serum sample into a sample buffer solution containing lipophilic fluorescent dye, wherein the dye can be specifically combined with lipoprotein; injecting a gel dye into a microfluidic electrophoresis chip, adding a to-be-detected blood sample, performing detecting on a microfluidic electrophoresis chip analyzer,sending the sample into a separation channel under the action of an external electric field and electroosmotic flow, and separating HDL in the to-be-detected sample into a plurality of sub-componentsunder the action of a molecular sieve and charges. According to the structure, the judgment accuracy of preeclampsia is improved.